A study looking at treatment for high risk neuroblastoma (HR/NBL2/SIOPEN) | Cancer Research UK
G-CSF counteracts chemotherapy toxicity in neuroblastoma - Document - Gale Academic OneFile
The International Neuroblastoma Risk Group (INRG) consensus... | Download Table
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Clinical impact of primary tumour 123ImIBG response to induction chemotherapy in children with high-risk neuroblastoma | International Journal of Clinical Oncology
Neuroblastoma - Chung - 2021 - Pediatric Blood & Cancer - Wiley Online Library
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. - Abstract - Europe PMC
Forest plot of comparison: 1 Rapid COJEC versus standard induction,... | Download Scientific Diagram
Thieme E-Books & E-Journals -
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial - The Lancet Oncology
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Treatment and management of newly diagnosed patients with high-risk neuroblastoma (not patients currently registered on HR-NBL-1
IJMS | Free Full-Text | MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue | Bone Marrow Transplantation
Management of neuroblastoma in limited-resource settings
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Neuroblastoma | British Association of Paediatric Surgeons
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
SOLUTION: Peinemann2016 - Studypool
Children | Free Full-Text | High-Risk Neuroblastoma Treatment Review
